Ultragenyx Pharmaceutical (RARE) Change in Intangibles (2018)
Ultragenyx Pharmaceutical (RARE) posted quarterly Change in Intangibles of $80.6 million for Q2 2018, down 38.0% quarter-over-quarter from $130.0 million in Q1 2018.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Change in Intangibles (2018) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Change in Intangibles for 1 consecutive years, with $80.6 million the latest figure, recorded in Q2 2018.
- In Q2 2018, Change in Intangibles changed N/A year-over-year to $80.6 million; the TTM figure through Dec 2018 stood at $210.6 million (changed N/A YoY), while the FY2019 annual figure was $314.2 million, up 84.49% from the prior year.
- Change in Intangibles slipped to $80.6 million in Q2 2018 per RARE's latest filing, from $130.0 million in the prior quarter.
- Across five years, Change in Intangibles topped out at $130.0 million in Q1 2018 and bottomed at $80.6 million in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | - |